HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?
Publication
, Journal Article
Muir, AJ
Published in: Nat Clin Pract Gastroenterol Hepatol
December 2005
Duke Scholars
Published In
Nat Clin Pract Gastroenterol Hepatol
DOI
ISSN
1743-4378
Publication Date
December 2005
Volume
2
Issue
12
Start / End Page
568 / 569
Location
England
Related Subject Headings
- Gastroenterology & Hepatology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Muir, A. J. (2005). HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy? Nat Clin Pract Gastroenterol Hepatol, 2(12), 568–569. https://doi.org/10.1038/ncpgasthep0337
Muir, Andrew J. “HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?” Nat Clin Pract Gastroenterol Hepatol 2, no. 12 (December 2005): 568–69. https://doi.org/10.1038/ncpgasthep0337.
Muir AJ. HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy? Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):568–9.
Muir, Andrew J. “HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?” Nat Clin Pract Gastroenterol Hepatol, vol. 2, no. 12, Dec. 2005, pp. 568–69. Pubmed, doi:10.1038/ncpgasthep0337.
Muir AJ. HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy? Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):568–569.
Published In
Nat Clin Pract Gastroenterol Hepatol
DOI
ISSN
1743-4378
Publication Date
December 2005
Volume
2
Issue
12
Start / End Page
568 / 569
Location
England
Related Subject Headings
- Gastroenterology & Hepatology
- 1103 Clinical Sciences